| Project/Area Number |
23791551
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
HIRASHIMA Kotaro 熊本大学, 医学部附属病院, 非常勤診療医師 (10594468)
|
|---|
| Research Collaborator |
BABA Hideo 熊本大学, 大学院・生命科学研究部, 教授 (20240905)
WATANABE Masayuki 熊本大学, 大学院・生命科学研究部, 准教授 (80254639)
BABA Yoshifumi 熊本大学, 医学部附属病院, 助教 (20599708)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Keywords | mTOR / RAD001 / 食道扁平上皮癌 / PI3K/Akt / cell cycle / cell growth / apoptosis / PI3K/AKT / mTOR阻害剤 / proliferation / 免疫染色 / 食道癌 / アポトーシス |
|---|
| Research Abstract |
The mammalian target of rapamycin (mTOR) plays central roles inthe regulation of cell growth and proliferation. The aberrant activation of mTOR inrelation to clinical outcome has been reported in several types of cancers. mTOR isincreasingly important as a potential target for anticancer therapy. Nonetheless, aprognostic feature of mTOR activation in esophageal squamous cell carcinoma remainsuncertain.
|
